Search for: "PAR PHARMACEUTICALS"
Results 221 - 240
of 303
Sort by Relevance
|
Sort by Date
25 Feb 2010, 11:18 am
That’s par for the course with this kind of thing. [read post]
28 Jan 2010, 4:51 am
Older adults are also less able to prevent pharmaceutical errors be [read post]
Pre-Post Podcast Series Preview: Litigation and E-Discovery Strategies: Meet & Confer Best Practices
4 Jan 2010, 3:48 am
., Senior Director, Legal, Compliance | Par Pharmaceutical, Inc.Moderator:Virginia P. [read post]
3 Dec 2009, 2:41 pm
The position is on par with the nation's drug czar. [read post]
2 Dec 2009, 11:05 am
The $74.4 million U.S. market for generic dronabinol is also highly concentrated, with only Watson and Par Pharmaceuticals currently supplying the drug. [read post]
28 Oct 2009, 5:00 am
The possibility always existed that the debt would trade at below par or that the company would lack the cash to repurchase the instruments. [read post]
18 Oct 2009, 5:42 pm
Judge Brown found that the patent in question, US Patent No. 5,565,473, was valid and enforceable, and [...]...FTC Sues Regarding AndroGel Patent Settlement The Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition to Solvay’s branded… [read post]
12 Oct 2009, 12:38 pm
Citigroup Global Market, Inc. has filed a motion to dismiss an action against it by KV Pharmaceuticals Co. arising out of sales of auction rate securities, according to an August 25 article in Law360 by Christine Caufield entitled "Citigroup Argues KV Pharma Knew ARS Risks. [read post]
7 Oct 2009, 9:59 pm
Sanofi originally filed suit against Sun, Sandoz, Actavis Inc., and Par Pharmaceutical Inc., among other generic manufacturers, in June 2007, accusing them of infringing Sanofi's patent covering Eloxatin ®, U.S. [read post]
15 Sep 2009, 9:55 pm
Purdue originally filed suit in August 2007 in the wake of Par Pharmaceutical's filing of an Abbreviated New Drug Application (ANDA) with the FDA, claiming that Par infringed Purdue's Ultram ® patents. [read post]
19 Aug 2009, 5:41 am
(Patent Docs) US: BIO files amicus brief in Bilski (Patent Docs) US: Jim Greenwood on data exclusivity and healthcare innovation (BiotechBlog) (IP Watchdog) (Patent Docs) US: European biosimilars market may hint at limited US threat (GenericsWeb) US: Chris Hansen on the Myriad lawsuit (Patents4Life) Products Effexor (Venlafaxine) – US: Wyeth files suit alleging Alphapharm’s Enlafax infringes its Venlafaxine patent; Generic Health, which recently registered… [read post]
12 Aug 2009, 3:03 am
Among other things, the article cites a source as saying that nonfinancial public companies still have $24 billion (par value) of ARS on their books. [read post]
31 Jul 2009, 1:48 pm
The Office website already offers a range of online interactive services on a par with and in some cases, exceeding those provided by other national patent offices in Europe. [read post]
8 Jul 2009, 7:04 am
– CAFC decision in Agilent Techs v Affymetrix concerning claims pertaining to ‘microarray hybridization’ (Gray on Claims) US: Counterclaims dismissed in Alzheimer’s Institute/ Mayo patent licensing dispute over transgenic mice (Patent Docs) Products (Tavanic) Levofloxacin – UK: EWCA upholds decision that Daiichi’s Levofloxacin patent and SPC both invalid: Generics (UK) Ltd v Daiichi Pharmaceutical Co Ltd and Daiichi… [read post]
8 Jun 2009, 9:55 pm
By Suresh Pillai -- Par Files Amended Complaint in Nascobal ® Suit Par Pharmaceuticals filed an amended complaint against Fleming & Co. [read post]
3 Jun 2009, 8:55 pm
The Eastern District of Virginia construed the claims and granted-in-part Lupin's motion for summary judgment of noninfringement, In the Illinois action, Abbott sued Sandoz (and Sandoz GmbH, Teva Pharmaceuticals, Ranbaxy Laboratories, Par Pharmaceutical) for infringement after they wanted to market generic versions of Omnicef. [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
29 May 2009, 1:10 pm
The Federal Court recently issued its judgment in NPS Pharmaceuticals, Inc v. [read post]
26 May 2009, 6:27 am
Amylin's public Indenture [2] contains a common change in control provision giving noteholders the right to put their notes to the company at par if "at any time Continuing Directors do not constitute a majority of the Company's Board of Directors". [read post]
